Skip to content

Inhibrx Biosciences

US · INBX #3022 by market cap Listed 2024
68.97 -5.36 -7.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 4 in the most recent period (2026/Q3).
  • Total institutional ownership fell 4.6 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
104.01% -4.56pp
Institutions
202 +4
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund40.86%
Hedge Fund24.92%
Public Company22.55%
Individual/Insider15.62%
VC/PE Fund10.88%
Government Pension Fund2.98%
Private Company0.90%
Sovereign Wealth Fund0.61%
Family Office/Trust0.19%

Top holders as of 2026-06-30

Viking Global Investors LP 9.40% · 1.38M sh
Morgan Stanley Investment Management Inc. 8.97% · 1.32M sh
Morgan Stanley 8.97% · 1.32M sh
Perceptive Advisors LLC 8.82% · 1.30M sh
Sanofi 7.87% · 1.16M sh
John Kayyem 7.30% · 1.07M sh
Mark Lappe 6.59% · 970.45K sh
HighTower Advisors, LLC 6.01% · 884.44K sh
Bank of America Corporation 5.72% · 841.14K sh
BlackRock 5.58% · 821.93K sh
Schonfeld Strategic Advisors LLC 4.74% · 697.59K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

27 filings tracked · 0 buys · 27 sells

NameRoleStake
John Kayyem Independent Director 7.30%
Mark Lappe Chairperson & CEO 6.59%
Douglas Forsyth Independent Director 1.54%
Kristiina Vuori Independent Director 0.14%
Kimberly Manhard Independent Director 0.05%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2024-05-29 Douglas Forsyth Independent Director Sale to Issuer -598,257 $30.00
2024-05-29 Douglas Forsyth Independent Director Derivative Sale to Issuer -62,259 --
2024-05-29 Kimberly Manhard Independent Director Derivative Sale to Issuer -65,759 --
2024-05-29 John Kayyem Independent Director Sale to Issuer -3,274,301 $30.00
2024-05-29 John Kayyem Independent Director Derivative Sale to Issuer -62,259 --
2024-05-29 Mark Lappe Chairperson & CEO Sale to Issuer -3,045,654 $30.00
2024-05-29 Mark Lappe Chairperson & CEO Derivative Sale to Issuer -245,000 --
2024-05-29 Kristiina Vuori Independent Director Derivative Sale to Issuer -60,000 --
2024-05-29 Brendan Eckelman Founder & Chief Scientific Officer Sale to Issuer -2,055,553 $30.00
2024-05-29 Brendan Eckelman Founder & Chief Scientific Officer Derivative Sale to Issuer -33,334 --
2024-05-29 Kelly Deck Chief Financial Officer Derivative Sale to Issuer -45,000 --
2024-05-27 Brendan Eckelman Founder & Chief Scientific Officer Open Market Disposition -300,000 $34.30
2024-05-21 Brendan Eckelman Founder & Chief Scientific Officer Other Derivative Disposition -5,010 $23.30–33.63
2024-05-05 Kelly Deck Chief Financial Officer Intent to Sell (Form 144) -19,711 $34.24
2024-03-25 Kelly Deck Chief Financial Officer Other Derivative Disposition -2,896 $10.52–34.16
2024-03-21 Kelly Deck Chief Financial Officer Intent to Sell (Form 144) -110 $35.00
2024-03-20 Kelly Deck Chief Financial Officer Intent to Sell (Form 144) -3,113 $35.09
2024-03-19 Kelly Deck Chief Financial Officer Intent to Sell (Form 144) -16,777 $35.02
2024-03-12 Brendan Eckelman Founder & Chief Scientific Officer Other Derivative Disposition -1,898 $33.63
2024-03-12 Kelly Deck Chief Financial Officer Other Derivative Disposition -32,431 $11.25

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Inhibrx Biosciences discussion 0 comments

Add a comment